FilingsTodayEnglewood Lab
At a glance
Englewood Lab filed 34 disclosures in the last 12 months, including 4 earnings, 1 insider and 1 5% holder. The most recent key filing was on Aug 10.
Revenue for 2025 was ₩152.4M, up 14.1% on 2024. Operating margin was 17.2% against 10.3% a year earlier. Debt was 38% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩68.5M and operating profit of ₩9.6M.
The 2025 annual report lists 153 employees with an average tenure of 4.8 years and average pay of ₩70.3M, #581 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩46 each on average. It paid ₩201 per common share in cash dividends, against ₩100 a year earlier (+101%). ㈜코스메카코리아 and related parties held 55.08% at year end.
From the 2025 annual report
Staff: 153 (71 men, 82 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩10.8B. Directors and auditors: 8, paid ₩365 in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩201 | ₩100 | ₩100 |
| Payout ratio | 16.1% | 10.2% | 9.6% |
| Yield (as filed) | 1.80% | 1.50% | 0.80% |
| Total cash dividends | ₩4B | ₩2B | ₩2B |
Largest shareholder
㈜코스메카코리아 holds 50.00%; with 4 related parties the group holds 55.08% of common shares at year end.
Auditor: 현대회계법인 · opinion: Unqualified.
Rankings: Dividend growth #75 of 917
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.